cystic fibrosis

Vertex’s Orkambi Safe and Effective for Treating CF F508del Mutation

Two Phase III clinical trials from Northwestern University’s Feinberg School of Medicine and Stanley Manne Children’s Research Institute at Ann Robert H. Lurie Children’s Hospital of Chicago tested a combination treatment plan in patients with cystic fibrosis. The results show that lumacaftor/ivacaftor, to be marketed under the…

Experimental Antibiotics Shown to Kill Bacterial Infection Frequently Found in Cystic Fibrosis

During the American Thoracic Society 2015 International Conference being held in Denver, Colorado, 15-20 of May, researchers from Oregon State University, Corvallis (OSU), and Aradigm Corporation will present a study entitled “Treatment of Mycobacterium Avium Subsp Hominissuis (MAH) Lung Infections with Liposome-Encapsulated Ciprofloxacin Resulted in Significant Decrease in Bacterial Load in the…

Spyryx Biosciences Raises $18 Million To Develop CF Therapy

Spyryx Biosciences, Inc. has successfully raised $18 million in Series A venture capital financing, which will be used to develop novel therapies to treat respiratory conditions such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). The funding was secured through deals with Canaan Partners, Hatteras Venture Partners and…